MD20210033A2 - Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 - Google Patents

Compuşi, compoziţii şi metode pentru modularea activităţii CDK9

Info

Publication number
MD20210033A2
MD20210033A2 MDA20210033A MD20210033A MD20210033A2 MD 20210033 A2 MD20210033 A2 MD 20210033A2 MD A20210033 A MDA20210033 A MD A20210033A MD 20210033 A MD20210033 A MD 20210033A MD 20210033 A2 MD20210033 A2 MD 20210033A2
Authority
MD
Moldova
Prior art keywords
compounds
methods
cdk9
compositions
modulating
Prior art date
Application number
MDA20210033A
Other languages
English (en)
Russian (ru)
Inventor
Петер МИКОЧИК
Джозеф ВАККА
Дэвид ФРИМАН
Эндрю Таскер
Original Assignee
Kronos Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio, Inc. filed Critical Kronos Bio, Inc.
Publication of MD20210033A2 publication Critical patent/MD20210033A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Invenţia se referă la compuşi, care modulează activitatea kinazei dependente de ciclină 9 (CDK9), compoziţii farmaceutice, care conţin astfel de compuşi, şi metode de utilizare a compuşilor şi/sau compoziţiilor farmaceutice pentru tratamentul, ameliorarea şi/sau prevenirea bolilor, care apar în rezultatul activităţii CDK9, de exemplu, bolilor hiperproliferative, bolilor infecţioase, induse de virus, şi bolilor cardiovasculare.Inhibitorii ai CDK9 reprezintă derivaţi de pirazolo[1,5-a]pirimidine şi sărurile lor, corespunzători formulei (I): (I).
MDA20210033A 2018-10-30 2019-10-29 Compuşi, compoziţii şi metode pentru modularea activităţii CDK9 MD20210033A2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
MD20210033A2 true MD20210033A2 (ro) 2021-10-31

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20210033A MD20210033A2 (ro) 2018-10-30 2019-10-29 Compuşi, compoziţii şi metode pentru modularea activităţii CDK9

Country Status (20)

Country Link
US (3) US11155560B2 (ro)
EP (1) EP3873911A4 (ro)
JP (1) JP7385658B2 (ro)
KR (1) KR20210068597A (ro)
CN (1) CN112996790B (ro)
AU (1) AU2019370200A1 (ro)
BR (1) BR112021008176A2 (ro)
CA (1) CA3118472A1 (ro)
CO (1) CO2021005502A2 (ro)
CR (1) CR20210202A (ro)
DO (1) DOP2021000066A (ro)
IL (1) IL282254A (ro)
MA (1) MA54092A (ro)
MD (1) MD20210033A2 (ro)
MX (1) MX2021004769A (ro)
PE (1) PE20212196A1 (ro)
PH (1) PH12021550857A1 (ro)
SG (1) SG11202104229WA (ro)
WO (1) WO2020092314A1 (ro)
ZA (1) ZA202102609B (ro)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019370200A1 (en) * 2018-10-30 2021-06-10 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
WO2021216828A1 (en) * 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
KR20240110634A (ko) * 2021-11-24 2024-07-15 크로노스 바이오, 인코포레이티드 (1s,3s)-n1-(5-(펜탄-3-일)피라졸로[1,5-a]피리미딘-7-일)시클로펜탄-1,3-디아민의다형체 및 염 형태
WO2024017365A1 (zh) * 2022-07-22 2024-01-25 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物的药学上可接受的盐和多晶型物及其应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
WO1998003510A1 (en) 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company AZOLO TRIAZINES AND PYRIMIDINES
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
CA2379633C (en) 1999-09-30 2006-06-20 Neurogen Corporation Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
MXPA04012245A (es) 2002-06-04 2005-09-30 Neogenesis Pharmaceuticals Inc Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026229A2 (en) * 2002-09-04 2004-04-01 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
NZ539165A (en) 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
EP1697369A1 (en) 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
AU2005272298A1 (en) * 2004-08-13 2006-02-16 Teijin Pharma Limited Pyrazolo[1,5-a]pyrimidine derivative
JP2008524330A (ja) 2004-12-21 2008-07-10 シェーリング コーポレイション ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
BRPI0712016A2 (pt) 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
EP2173346A2 (en) 2007-06-27 2010-04-14 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
CN102143746A (zh) * 2008-07-03 2011-08-03 埃克塞利希斯股份有限公司 Cdk 调节剂
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8575177B2 (en) 2009-12-04 2013-11-05 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
KR101478889B1 (ko) 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
WO2011108689A1 (ja) 2010-03-05 2011-09-09 協和発酵キリン株式会社 ピラゾロピリミジン誘導体
PE20130395A1 (es) 2010-06-24 2013-04-10 Gilead Sciences Inc Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
CN104066736B (zh) 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
SG10201606581RA (en) 2012-02-17 2016-09-29 Millennium Pharm Inc Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3125907A4 (en) 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107530329B (zh) 2015-03-09 2021-10-08 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3356330B1 (en) 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US11112410B2 (en) 2016-04-13 2021-09-07 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
US20190060296A1 (en) * 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses
BR112020001714A2 (pt) 2017-07-28 2020-07-21 Nimbus Lakshmi, Inc. inibidores de tyk2 e usos dos mesmos
AU2019370200A1 (en) * 2018-10-30 2021-06-10 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity

Also Published As

Publication number Publication date
US11155560B2 (en) 2021-10-26
US20220002305A1 (en) 2022-01-06
US20240132506A1 (en) 2024-04-25
WO2020092314A1 (en) 2020-05-07
CR20210202A (es) 2022-02-08
DOP2021000066A (es) 2021-10-31
IL282254A (en) 2021-05-31
PE20212196A1 (es) 2021-11-16
EP3873911A4 (en) 2022-06-22
PH12021550857A1 (en) 2021-12-06
SG11202104229WA (en) 2021-05-28
JP2022505268A (ja) 2022-01-14
CN112996790A (zh) 2021-06-18
CA3118472A1 (en) 2020-05-07
KR20210068597A (ko) 2021-06-09
AU2019370200A1 (en) 2021-06-10
MA54092A (fr) 2021-09-08
BR112021008176A2 (pt) 2021-08-03
CN112996790B (zh) 2023-11-03
CO2021005502A2 (es) 2021-09-20
US11845754B2 (en) 2023-12-19
US20200131189A1 (en) 2020-04-30
ZA202102609B (en) 2023-02-22
EP3873911A1 (en) 2021-09-08
MX2021004769A (es) 2021-08-24
JP7385658B2 (ja) 2023-11-22

Similar Documents

Publication Publication Date Title
MD20210033A2 (ro) Compuşi, compoziţii şi metode pentru modularea activităţii CDK9
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
CA2962914C (en) Compounds and compositions for modulating egfr mutant kinase activities
EA201991884A3 (ru) Ингибиторы g12c kras
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EA202091372A1 (ru) Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
WO2015200677A3 (en) Prmt5 inhibitors and uses thereof
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
MY193511A (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
EA201691930A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-α]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-α][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
MX2022008627A (es) Pirazolo-pirimidinas sustituidas y usos de las mismas.
PH12017501334B1 (en) 3,5-diaminopyrazole kinase inhibitors
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета
MX2021000917A (es) Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe.